A randomized trial in 300 infants found that a Sabin strain-based inactivated polio vaccine induced seroconversion rates of 91.58% to 100% across ten poliovirus strains. The study reported no vaccine-related serious adverse events. The results support the vaccine’s ability to generate cross-strain neutralizing antibodies in early life, a critical requirement for durable protection in settings where circulating virus strains can vary. Investigators used the randomized design to assess immunogenicity and safety outcomes across tested poliovirus strains. For biotech and vaccine stakeholders, the data provide another benchmark for next-generation polio immunization strategies aimed at broad serotype coverage without adding safety signals.